Top Ranked Value Stocks To Buy For December 30th

Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 30th:

Navios Maritime Partners L.P. (NMM): This owner and operator of dry cargo vessels has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 4.6% over the last 60 days.

Navios Maritime Partners LP Price and Consensus

Navios Maritime has a price-to-earnings ratio (P/E) of 11.45 compared with 22.40 for the industry. The company possesses a Value Score of A.

Navios Maritime Partners LP PE Ratio (TTM)

Verso Corporation (VRS): This producer of specialty and graphic papers, packaging and pulp has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 86.2% over the last 60 days.

Verso Corporation Price and Consensus

Verso has a price-to-earnings ratio (P/E) of 5.65 compared with 10.10 for the industry. The company possesses a Value Score of A.

Verso Corporation PE Ratio (TTM)

Innoviva, Inc. (INVA): This developer of pharmaceuticals has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 18.7% over the last 60 days.

Innoviva, Inc. Price and Consensus

Innoviva has a price-to-earnings ratio (P/E) of 7.02 compared with 13.80 for the industry. The company possesses a Value Score of B.

Innoviva, Inc. PE Ratio (TTM)

See the full list of top ranked stocks here

Learn more about the Value score and how it is calculated here.

Find more top income stocks with some of our great premium screens.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>